Small molecule anti-cancer therapy developer BlossomHill (BLSM.US) sets IPO price at $15-17 per share, aiming to raise $125 millions
智通财经2026/08/04 09:01According to Golden Ten Data, BlossomHill Therapeutics, a biotechnology company focused on developing small molecule cancer therapies and currently preparing for phase II clinical trials, announced the terms of its initial public offering (IPO) on Monday. The company plans to issue 7.8 million shares in a price range of $15 to $17 per share, raising $125 million. BlossomHill Therapeutics intends to list on Nasdaq under the ticker symbol "BLSM".
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Brent crude oil futures main contract hits $97 per barrel, up 1.21% on the day
The US Dollar Index fell below the 98 mark, down 0.26% on the day.
European natural gas and EU carbon prices rise, UK natural gas up 1.72%
Crypto prices
More
